Isomorphic Labs has completed a $5 billion Series C financing round to advance AI-driven drug design. The round was co-led by Greenoaks and Sequoia Capital, with Alphabet participating once again. The fresh capital will be used to advance its first wave of therapeutic programs into clinical trials.